Sunshine Biopharma (SBFM) Total Non-Current Liabilities (2015 - 2026)
Sunshine Biopharma (SBFM) reported Total Non-Current Liabilities of $535614.0 for Q1 2026, down 25.84% on a YoY basis from $722199.0 in Q1 2025, and down 10.25% quarter-over-quarter from $596785.0 in Q4 2025.
Sunshine Biopharma (SBFM) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Sunshine Biopharma has reported Total Non-Current Liabilities for 10 years, with the latest figure at $535614.0 in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 25.84% year-over-year to $535614.0; the trailing twelve-month figure through Mar 2026 stood at $535614.0 (down 25.84% YoY), and the FY2025 full-year result was $596785.0, down 19.86% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $535614.0, down from $596785.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $744724.0 in Q4 2024, with the low at $489027.0 in Q3 2024.
- Historically, Total Non-Current Liabilities has averaged $618336.9 across 5 years, with a median of $617713.5 in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 63.93% — and 2025, when it jumped 38.09%.
- Sunshine Biopharma's Total Non-Current Liabilities stood at $685264.0 in 2022, then slipped by 14.23% to $587764.0 in 2023, then advanced by 26.7% to $744724.0 in 2024, then slipped by 19.86% to $596785.0 in 2025, then retreated by 10.25% to $535614.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $535614.0 (Q1 2026), $596785.0 (Q4 2025), and $636708.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Sunshine Biopharma | 10.94 Mn | 4.03 Mn | 2.18 Mn | 535,614.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 535,614.00 |
| Dec 31, 2025 | 596,785.00 |
| Sep 30, 2025 | 636,708.00 |
| Jun 30, 2025 | 706,530.00 |
| Mar 31, 2025 | 722,199.00 |
| Dec 31, 2024 | 744,724.00 |
| Sep 30, 2024 | 489,027.00 |
| Jun 30, 2024 | 511,635.00 |
| Mar 31, 2024 | 545,697.00 |
| Dec 31, 2023 | 587,764.00 |
| Sep 30, 2023 | 598,719.00 |
| Jun 30, 2023 | 639,882.00 |
| Mar 31, 2023 | 656,168.00 |
| Dec 31, 2022 | 685,264.00 |
| Dec 31, 2021 | 1.90 Mn |
| Mar 31, 2019 | 338,973.00 |
| Dec 31, 2018 | 289,847.00 |
| Dec 31, 2016 | 274,104.00 |
| Dec 31, 2015 | 1.27 Mn |